Kosuke Kajitani1,2, Kazuyuki Yanagimoto3, Yusaku Nakabeppu4. 1. Counseling and Health Center, Faculty of Arts and Science, Kyushu University, 6-1 Kasuga-koen, Kasuga, Fukuoka, 816-8580, Japan. kkajitani@artsci.kyushu-u.ac.jp. 2. Department of Psychiatry, Hakomatsu Hospital, 1-3-9 Higashi-ku, Hakomatsu, Fukuoka, 812-0061, Japan. kkajitani@artsci.kyushu-u.ac.jp. 3. Department of Psychiatry, Hakomatsu Hospital, 1-3-9 Higashi-ku, Hakomatsu, Fukuoka, 812-0061, Japan. 4. Division of Neurofunctional Genomics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Higashi-ku, Maidashi, Fukuoka, 815-8582, Japan.
Abstract
BACKGROUND: Previous studies have reported that galectin-3 is involved in inflammatory processes in the central nervous system and that neuroinflammation may play a role in the pathogenesis of schizophrenia. However, the link between schizophrenia and various galectins is unclear. OBJECTIVE: The objective of the present study is to determine whether galectin, a well-known lectin protein that binds to μ-galactoside, is associated with chronic schizophrenia. METHODS: Thirty-six patients with schizophrenia and 36 healthy controls participated in this study. Schizophrenia symptoms were assessed using the Brief Psychiatry Rating Scale (BPRS). Serum galectin-1 and galectin-3 levels were evaluated using ELISA and compared between the participant groups. Correlation analyses were also performed to examine the relationship between BPRS scores and each galectin level. RESULTS: Serum galectin-3 levels were significantly higher in patients with schizophrenia than they were in controls (p = 0.009, d = 0.640); however, serum galectin-1 levels were not significantly different between the groups (p = 0.513). No significant correlation was identified between serum galectin-3 level and the total BPRS score; however, a significant positive correlation was found between the serum galectin-3 level and the positive symptom score of the BPRS (ρ = 0.355; p = 0.033). Additionally, a significant negative correlation was identified between serum galectin-3 levels and the negative symptom score of the BPRS (ρ = -0.387; p = 0.020). CONCLUSIONS: Given the high serum levels of galectin-3 found in patients with schizophrenia compared with that in controls, these findings may support the inflammation hypothesis of schizophrenia.
BACKGROUND: Previous studies have reported that galectin-3 is involved in inflammatory processes in the central nervous system and that neuroinflammation may play a role in the pathogenesis of schizophrenia. However, the link between schizophrenia and various galectins is unclear. OBJECTIVE: The objective of the present study is to determine whether galectin, a well-known lectin protein that binds to μ-galactoside, is associated with chronic schizophrenia. METHODS: Thirty-six patients with schizophrenia and 36 healthy controls participated in this study. Schizophrenia symptoms were assessed using the Brief Psychiatry Rating Scale (BPRS). Serum galectin-1 and galectin-3 levels were evaluated using ELISA and compared between the participant groups. Correlation analyses were also performed to examine the relationship between BPRS scores and each galectin level. RESULTS: Serum galectin-3 levels were significantly higher in patients with schizophrenia than they were in controls (p = 0.009, d = 0.640); however, serum galectin-1 levels were not significantly different between the groups (p = 0.513). No significant correlation was identified between serum galectin-3 level and the total BPRS score; however, a significant positive correlation was found between the serum galectin-3 level and the positive symptom score of the BPRS (ρ = 0.355; p = 0.033). Additionally, a significant negative correlation was identified between serum galectin-3 levels and the negative symptom score of the BPRS (ρ = -0.387; p = 0.020). CONCLUSIONS: Given the high serum levels of galectin-3 found in patients with schizophrenia compared with that in controls, these findings may support the inflammation hypothesis of schizophrenia.
Authors: Miguel Angel Burguillos; Martina Svensson; Tim Schulte; Antonio Boza-Serrano; Albert Garcia-Quintanilla; Edel Kavanagh; Martiniano Santiago; Nikenza Viceconte; Maria Jose Oliva-Martin; Ahmed Mohamed Osman; Emma Salomonsson; Lahouari Amar; Annette Persson; Klas Blomgren; Adnane Achour; Elisabet Englund; Hakon Leffler; Jose Luis Venero; Bertrand Joseph; Tomas Deierborg Journal: Cell Rep Date: 2015-03-05 Impact factor: 9.423
Authors: Celene M O S Alves; Deise A O Silva; Ana Elisa C S Azzolini; Cleni M Marzocchi-Machado; Julianne V Carvalho; Ana Cláudia A M Pajuaba; Yara Maria Lucisano-Valim; Roger Chammas; Fu-Tong Liu; Maria C Roque-Barreira; José R Mineo Journal: Immunobiology Date: 2009-08-31 Impact factor: 3.144
Authors: K Kajitani; H Nomaru; M Ifuku; N Yutsudo; Y Dan; T Miura; D Tsuchimoto; K Sakumi; T Kadoya; H Horie; F Poirier; M Noda; Y Nakabeppu Journal: Cell Death Differ Date: 2008-11-14 Impact factor: 15.828
Authors: Golam M Khandaker; Lesley Cousins; Julia Deakin; Belinda R Lennox; Robert Yolken; Peter B Jones Journal: Lancet Psychiatry Date: 2015-02-25 Impact factor: 27.083
Authors: Milica M Borovcanin; Slavica M Janicijevic; Ivan P Jovanovic; Nevena Gajovic; Nebojsa N Arsenijevic; Miodrag L Lukic Journal: Front Psychiatry Date: 2018-06-22 Impact factor: 4.157
Authors: Slavica Minic Janicijevic; Ivan P Jovanovic; Nevena M Gajovic; Milena M Jurisevic; Monojit Debnath; Nebojsa N Arsenijevic; Milica M Borovcanin Journal: World J Psychiatry Date: 2022-09-19
Authors: Santiago P Mendez-Huergo; Pablo F Hockl; Juan C Stupirski; Sebastián M Maller; Luciano G Morosi; Nicolás A Pinto; Ana M Berón; Jorge L Musuruana; Gustavo G Nasswetter; Javier A Cavallasca; Gabriel A Rabinovich Journal: Front Immunol Date: 2019-01-09 Impact factor: 7.561